1. Home
  2. SBR vs GERN Comparison

SBR vs GERN Comparison

Compare SBR & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sabine Royalty Trust

SBR

Sabine Royalty Trust

HOLD

Current Price

$75.33

Market Cap

1.1B

Sector

Energy

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.71

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBR
GERN
Founded
1982
1990
Country
United States
United States
Employees
N/A
229
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SBR
GERN
Price
$75.33
$1.71
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$2.17
AVG Volume (30 Days)
41.1K
18.5M
Earning Date
05-14-2026
05-06-2026
Dividend Yield
6.51%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$26.91
Revenue Next Year
N/A
$43.75
P/E Ratio
$12.77
N/A
Revenue Growth
N/A
N/A
52 Week Low
$62.23
$1.04
52 Week High
$84.39
$2.01

Technical Indicators

Market Signals
Indicator
SBR
GERN
Relative Strength Index (RSI) 55.02 55.63
Support Level $75.29 $1.24
Resistance Level $77.08 $1.72
Average True Range (ATR) 1.73 0.10
MACD -0.10 0.02
Stochastic Oscillator 65.39 69.58

Price Performance

Historical Comparison
SBR
GERN

About SBR Sabine Royalty Trust

Sabine Royalty Trust formed to receive Sabine Corporation's royalty and mineral interests, including landowner's royalties, overriding royalty interests, minerals production payments and any other similar, non-participatory interests, in certain Royalty Properties. The trusts producing and proved undeveloped oil and gas royalty properties are located in Florida, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: